logo-loader
viewOpen Orphan PLC

Investor Event Attendance and Presentation

/**/ sup{font-size:80%}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .ak{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.ak{}p.bb{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm}span.bc{font-size:11.0pt; font-family:"Calibri","sans-serif"}p.bd{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center}span.ax{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black}p.be{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";text-align: center}span.av{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}p.bf{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; font-weight: bold; text-align: center}p.bg{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify} span.as{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}p.o,li.o,div.o{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}span.aq{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.ap{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.bh{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold}p.k,li.k,div.k{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}span.an{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}p.bi{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: justify}p.bj{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}span.al{color:black} /**/
RNS Number : 0482P
Open Orphan PLC
08 October 2019
 

8 October 2019

Open Orphan Plc

("Open Orphan" or the "Company")

Investor Event Attendance and Presentation

Open Orphan presents at Shares Investor Evening, Manchester

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at Shares Investor Evening at Macdonald Manchester Hotel, Manchester, M1 2PG from 18:00 on Thursday 10th October.

Cathal Friel, Open Orphan's Chief Executive Officer, will be in attendance and will be presenting to update existing and potential investors on the Company's business plans for 2019.

The event will provide an opportunity for investors to hear about the progress being made by the Company following the reverse takeover of Venn Life Sciences and the potential for Open Orphan moving forward.

A link to the presentation will be made available on the Company website following the event.

For further information on the event, please visit the event website https://www.sharesmagazine.co.uk/events/event/shares-investor-evening-manchester-101019

Enquiries:

Open Orphan Plc Tel: +353 (0)1 6440007
Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363
Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen

Notes to Editors:

Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAUGGGUUUPBGQM

Quick facts: Open Orphan PLC

Price: 5.6

Market: AIM
Market Cap: £14.26 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

hVIVO merger with Open Orphan 'gives it the chance to achieve profitability'

hVIVO PLC's (LON:HVO) Dr Trevor Phillips caught up with Proactive London's Andrew Scott following the news they're to merge with Open Orphan PLC (LON:ORPH). Open Orphan intends to maintain the existing research and development activities of hVIVO, relative to supporting hVIVO's clinical...

4 days, 11 hours ago

RNS

Form 8.3 - Open Orphan PLC

1 day, 9 hours ago

Form 8.3 - Open Orphan plc

1 day, 14 hours ago

Form 8.3 - Open Orphan PLC

2 days, 4 hours ago

Form 8.3 - Open Orphan

3 days, 5 hours ago

Form 8.5 (EPT/NON-RI)

3 days, 9 hours ago

Form 8.3 - Open Orphan

3 days, 10 hours ago

Form 8 (OPD)

3 days, 14 hours ago

Form 8 (DD) Open Orphan plc

4 days, 4 hours ago